Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men

Irie J, Inagaki E, Fujita M, Nakaya H, Mitsuishi M, Yamaguchi S · Endocrine Journal

The first human NMN administration study. Single oral doses of 100, 250 and 500 mg produced no clinical symptoms and no change in heart rate, blood pressure, oxygen saturation or body temperature, and left ophthalmic examination and sleep-quality score unchanged. Serum bilirubin rose and serum creatinine, chloride and blood glucose fell, all within normal ranges and independently of dose. Plasma N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide rose dose-dependently, which is the evidence that the NMN was absorbed and metabolised.

Population

Healthy Japanese men

Intervention

Single oral doses of 100, 250 and 500 mg NMN, each followed for 5 hours

Comparator

None — single-arm dose escalation

Limitations

Ten men, single doses, no control arm, five hours of follow-up. Neither plasma NMN nor tissue NAD+ was measured, so absorption is inferred from two downstream metabolites rather than observed; the authors name that as the study's first limitation. The compound was supplied by an NMN manufacturer that also funds one author's research, three authors are employed by a pharmaceutical company, and one is an inventor on NMN and NMN-transporter patents licensed to two firms.